Once‐weekly semaglutide use in patients with type 2 diabetes: real‐world data from the SURE Italy observational study
Raffaele Napoli,Cesare Berra,Andrei‐Mircea Catarig,Chiara Di Loreto,Emily Donatiello,Tina Landsvig Berentzen,Dario Pitocco,Francesco Giorgino
DOI: https://doi.org/10.1111/dom.15020
2023-02-16
Diabetes, Obesity and Metabolism
Abstract:Aims SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study, investigated once‐weekly (OW) semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and methods Adults with T2D and ≥1 documented HbA1c level within 12 weeks of semaglutide initiation were enrolled. The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Other endpoints included changes in body weight (BW), waist circumference and patient‐reported outcomes (PROs), and the proportion of patients achieving HbA1c <7.0% or <6.5%, weight loss ≥5% and a post‐hoc composite endpoint (HbA1c reduction of ≥1%‐point and weight loss ≥5%). These endpoints were reported for patients on semaglutide at EOS (effectiveness analysis set [EAS]). Safety data were reported in the full analysis set (FAS). Results Of 579 patients who initiated semaglutide (FAS), 491 completed the study on treatment (EAS). Mean baseline HbA1c was 8.0%, and 20.7% (120/579) of patients had HbA1c <7.0%. Mean semaglutide dose at EOS was 0.66 ± 0.28 mg. In the EAS, mean HbA1c and BW decreased by 1.1%‐point (95% confidence interval [CI] 1.20,1.05; p<0.0001) and 4.2 kg (95% CI 4.63,3.67; p<0.0001), respectively. At EOS, 61.7% and 40.8% of patients achieved HbA1c <7.0% and <6.5%, respectively, 40.5% achieved weight loss ≥5% and 25.3% achieved the post‐hoc composite endpoint. PROs improved from baseline to EOS. No new safety concerns were identified. Conclusions In routine clinical practice in Italy, patients with T2D treated with OW semaglutide for 30 weeks achieved clinically significant improvements in HbA1c, BW and other outcomes. This article is protected by copyright. All rights reserved.
endocrinology & metabolism